FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome ...Middle East

WASHINGTON, Dec. 1, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ® (tasimelteon) capsule and liquid formulations for the treatment of adults and children, respectively, with...

Hence then, the article about fda approves hetlioz tasimelteon for the treatment of nighttime sleep disturbances in smith magenis syndrome was published today ( Wednesday 02/12/2020 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome )

Also on site :

• ChatGPT uninstalls surged by 295% after DoD deal
• White House Mocks Kesha Over Singer’s Outrage About “Disgusting” Use Of Song In Military Posting; She Responds: “Stop Using My Music, Perverts”
• Cursor has reportedly surpassed $2B in annualized revenue